-
Lancet Child Health: Ear temperature 39.0 c as diagnostic criteria for reducing fever in children with chemotherapy neutrope%
Time of Update: 2020-06-05
Neutlyte cell-reduced fever is the most common complication of chemotherapy for cancer, and the temperature limit systos for fever is clinically different Higher limits avoid unnecessary diagnosis
-
ASCO 2020 . . . Pembrolizumab or alternative chemotherapy status in first-line treatment in MSI-H/dMMR CRC
Time of Update: 2020-06-05
On the second day of the 2020 American Society of Clinical Oncology (ASCO) annual meeting, Thierry Andre, on behalf of his team, published the Pym monoantigen and chemotherapy combined with microsa
-
Blood: Myc's Prognosis for HIV-NHLs treated with EPOCH-Vorinostat
Time of Update: 2020-06-05
EPOCH is the preferred option for HIV-NHLs, usually EBV plus or HHV-8 plus Histone deacetylase (HDAC) inhibitor Volinol interferes with the incubation period of EBV/HHV-8, enhances chemotherapy-ind
-
Preoperative restive fMRI describes the primary sensory motor cortex in glioma patients
Time of Update: 2020-06-05
Functional magnetic resonance imaging (functional magnetic resonance, fMRI) is of great significance for neurosurgery Some studies have suggested that task function magnetic resonance imaging (task fM
-
"Greedy" cancer cells: the energy produced by glycolysis to multiply and spread
Time of Update: 2020-06-05
Introduction: Sugar is the main food of cancer cells, sugar enters the body will be hydrolyzed into glucose, all our body's cells (including cancer cells) need glucose to provide energy Cancer cell
-
NAT CELL BIO: Liver cell aging secretions promote tumor development
Time of Update: 2020-06-05
To date, we are not fully aware of the interaction between liver cell metabolic disorders and cells in the tumor microenvironment, as well as the effects on liver tumors recently, researchers fou
-
Blood: Metabolic-based cancer treatment - Aldh3a2 inhibition
Time of Update: 2020-06-05
Metabolic changes in cancer represent the aggregate effect of cancer-causing mutations The researchers hypothesized that in an in vitro system that simulated a bone marrow microenvironment, the uni
-
ASCO 2020- Precision Treatment of Childhood Oncology Gets New Boost! Priority algorithm is feasible
Time of Update: 2020-06-05
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) has begun, and this academic feast has won the attention of oncologists around the world The most-watched summary of the
-
Sci Sign: "Greedy" cancer cells multiply and spread through the energy produced by glycolysis
Time of Update: 2020-06-05
Introduction: Sugar is the main food of cancer cells, sugar enters the body will be hydrolyzed into glucose, all our body's cells (including cancer cells) need glucose to provide energy Cancer cell
-
ASCO 2020 advanced urinary skin cancer has made new progress, Avelumab maintenance treatment combined BSC can extend the total survival period by 7.1 months!
Time of Update: 2020-06-05
The 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) is drawing to a close, and this academic feast has won the attention of oncologists around the world The most-watched sum
-
Nature and Immunity: Explain the process of depletion of T-cells and develop more effective immunotherapy
Time of Update: 2020-06-05
June 3, 2020 / bioON/bioON/ -- Mapping the life cycle of immune cells that have lost their vitality in the fight against cancer, giving researchers at the University of Pennsylvania School of Medic
-
Ibrance Co-Standard Therapy for Breast Cancer: Not Reaching Major End
Time of Update: 2020-06-05
Ibrance (Palbociclib) has failed to significantly improve disease-free survival (DFS) (DFS) when it comes to treating patients with hormone receptor (HR)-positive/HER2-negative early breast cancer,
-
FDA approves CYRAMZA (ramucirumab) first-line treatment of metastatic EGFR mutation non-small cell lung cancer
Time of Update: 2020-06-05
About 50% of non-small cell lung cancer (NSCLC) patients had advanced or metastatic diseases at the time of first diagnosis, and the five-year survival rate in patients with metastatic NSCLC was 6%
-
Gut: Colon and rectal cancer survival rates in high-income countries
Time of Update: 2020-06-05
In a recent study published in Gut, an authoritative journal on digestive diseases, researchers aim to provide the latest estimates of the survival rates of colon and rectal cancer patients in seve
-
Blood: Glucocorticoids enhance anti-FLT3 mutation AML activity in FLT3 inhibitors
Time of Update: 2020-06-05
FLT3 is a gene with frequent mutations that are closely related to poor prognosis of acute myeloid leukemia (AML) Although most AML patients initially respond to FLT3 inhibitor therapy, they eventu
-
PNAS: The team of Gao Guoquan of Zhongshan University found that metformin is effective against KRAS mutant colorectal cancer
Time of Update: 2020-06-05
For patients with metastatic colorectal cancer (mCRC), the overall survival rate was poor, especially in patients with KRAS tumor mutations, despite the use of Ilitocon or Osaliplatinum-based chemo
-
To starve cancer cells? Diettherapy is likely to be a short-term solution to cancer treatment!
Time of Update: 2020-06-05
The topic of what we should eat and what we should eat and what we should eat has been going on for a long time The Greeks and Romans once advocated a moderate diet as a way to live a long life Ove
-
Pediatr Blood Cancer: The Effectiveness of Neutlyte Cell Reduction Diet and Food Safety Guidelines for Infection Rates in Pediatric Tumor Patients
Time of Update: 2020-06-05
The neutrophil diet (ND) is designed to prevent bacteria from entering the host's gastrointestinal tract and reduce infection In the absence of evidence to support ND, pediatric oncologists are sti
-
Lancet respir med: Tepotinib combines gifitinib to treat EGFR-Met mutant non-small cell lung cancer
Time of Update: 2020-06-05
Tepotinib, a highly selective oral MET inhibitor, recently examined the efficacy and safety of Tepotinib-gifitinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC), who resisted EGFR
-
BMJ: Study on the risk of leaching breast cancer and breast cancer death in patients with breast catheter in situ cancer
Time of Update: 2020-06-05
Researchers recently examined the long-term risk of breast cancer and death from breast cancer after screening for breast catheterining in symfire (DCIS) study using NHS breast screening program